Regeneron Pharmaceuticals (REGN) Operating Income (2009 - 2026)

Regeneron Pharmaceuticals has reported Operating Income for 18 years, with the latest figure at $642.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 8.65% year-over-year to $642.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 billion (down 5.27% YoY), and the FY2025 full-year result was $3.6 billion, down 10.34% from the prior year.
• Operating Income for Q1 2026 stood at $642.9 million, down from $879.9 million in the prior quarter.
• The five-year high for Operating Income was $1.3 billion in Q1 2022, with the low at $591.7 million in Q1 2025.
• Average Operating Income over 5 years is $999.9 million, with a median of $1.0 billion recorded in 2025.
• Peak annual rise in Operating Income reached 13.1% in 2022, while the deepest fall reached 66.84% in 2022.
• Tracing REGN's Operating Income over 5 years: stood at $1.1 billion in 2022, then declined by 15.16% to $972.9 million in 2023, then grew by 1.78% to $990.2 million in 2024, then dropped by 11.14% to $879.9 million in 2025, then dropped by 26.93% to $642.9 million in 2026.
• The last three Operating Income figures came in at $642.9 million (Q1 2026), $879.9 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.

Peer Comparison